Company news
Entera Bio Ltd. news in 2026
Entera Bio Ltd.'s news releases, calls and decks from 2026, newest first.
Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors
October 27, 2026
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
October 13, 2026
Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
October 8, 2026
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
October 6, 2026
Correction: Entera to Participate in Upcoming Fall Investor Conferences
August 27, 2026
Entera to Participate in Upcoming Fall Investor Conferences
August 27, 2026
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
August 18, 2026
Entera Announces Second Quarter 2026 Financial Results and Business Updates
August 7, 2026
Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
August 4, 2026
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
July 31, 2026
Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE
July 28, 2026
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
July 27, 2026
America's Osteoporosis Crisis and the Oral Peptide Player You Should Watch (NASDAQ: ENTX)
July 7, 2026
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
June 22, 2026
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
June 16, 2026
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
June 15, 2026
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
May 28, 2026
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
May 8, 2026
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
April 14, 2026
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
April 1, 2026
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
March 26, 2026
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
March 4, 2026
Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference
February 25, 2026
Entera Bio Announces Open Market Purchases of Company Stock by Board Members
February 11, 2026
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
February 9, 2026
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
February 4, 2026
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
January 21, 2026